Tempest Therapeutics, Inc.

NasdaqCM:TPST Stock Report

Market Cap: US$28.2m

Tempest Therapeutics Future Growth

Future criteria checks 0/6

Tempest Therapeutics's earnings are forecast to decline at 7.3% per annum while its annual revenue is expected to grow at 79.2% per year. EPS is expected to grow by 7% per annum.

Key information

-7.3%

Earnings growth rate

7.0%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate79.2%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Apr 2025

Recent future growth updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

Earnings and Revenue Growth Forecasts

NasdaqCM:TPST - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-68N/A-143
12/31/2026N/A-64N/A-145
12/31/2025N/A-51N/A-205
12/31/2024N/A-42-33-33N/A
9/30/2024N/A-36-29-29N/A
6/30/2024N/A-32-26-25N/A
3/31/2024N/A-30-27-26N/A
12/31/2023N/A-29-28-27N/A
9/30/2023N/A-31-28-28N/A
6/30/2023N/A-33-31-30N/A
3/31/2023N/A-35-33-32N/A
12/31/2022N/A-36-32-31N/A
9/30/2022N/A-34-33-33N/A
6/30/2022N/A-34-35-35N/A
3/31/2022N/A-31-27-27N/A
12/31/2021N/A-28-26-26N/A
9/30/2021N/A-25-22-22N/A
6/30/2021N/A-22-15-15N/A
3/31/2021N/A-20-20-20N/A
12/31/2020N/A-19-19-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TPST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TPST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TPST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TPST is forecast to have no revenue next year.

High Growth Revenue: TPST is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TPST's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/25 22:49
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tempest Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC
Aydin HuseynovLadenburg Thalmann & Company